![www.prnewswire.com](/interact/proxy.php?image=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F2347275%2FPelage_Pharmaceuticals_Logo.jpg%3Fp%3Dfacebook&hash=c7cdb616943ba6bc526b8a32056c9557&return_error=1)
Pelage Pharmaceuticals Advances Clinical Program with First Patients Dosed in Phase 2 Study for Hair Loss and GV-Led $14M Series A-1
/PRNewswire/ -- Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, today announced...
![www.prnewswire.com](/interact/proxy.php?image=https%3A%2F%2Fwww.prnewswire.com%2Fcontent%2Fdam%2Fprnewswire%2Ficons%2F2019-Q4-PRN-Icon-32-32.png&hash=89aa278073eb9abe36a24ccd0de85c46&return_error=1)
New stuff. It targets hair follicle stem cells directly via a very crucial pathway.